Alphatec (ATEC) Projected to Post Quarterly Earnings on Thursday

Alphatec (NASDAQ:ATEC) is anticipated to post its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Alphatec to post earnings of $0.0951 per share and revenue of $225.16 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Alphatec (NASDAQ:ATEC) last released its earnings results on Tuesday, August 4th. The medical technology company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. Alphatec had a negative net margin of 13.49% and a negative return on equity of 6,752.24%. The firm had revenue of $213.51 million during the quarter, compared to analyst estimates of $211.26 million. During the same period last year, the business earned $0.02 earnings per share. The business’s revenue was up 15.1% on a year-over-year basis. On average, analysts expect Alphatec to post ($0.45) EPS for the current fiscal year and $0.03 EPS for the next fiscal year.

Alphatec Stock Down 1.9%

Shares of ATEC opened at $10.90 on Tuesday. The business’s 50 day moving average price is $10.09 and its 200-day moving average price is $10.84. Alphatec has a 52 week low of $6.82 and a 52 week high of $23.29. The stock has a market cap of $1.68 billion, a P/E ratio of -15.35 and a beta of 0.78.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Stifel Nicolaus lowered their price objective on Alphatec from $16.00 to $13.00 and set a “buy” rating for the company in a research note on Wednesday, July 8th. UBS Group boosted their target price on Alphatec from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Stephens initiated coverage on Alphatec in a research note on Thursday, July 23rd. They issued an “overweight” rating and a $15.00 target price on the stock. Wall Street Zen downgraded Alphatec from a “buy” rating to a “hold” rating in a report on Sunday, October 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alphatec in a report on Monday, August 3rd. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Alphatec has a consensus rating of “Moderate Buy” and an average target price of $17.40.

Insider Buying and Selling at Alphatec

In other Alphatec news, General Counsel Tyson Marshall sold 8,168 shares of Alphatec stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $9.65, for a total value of $78,821.20. Following the completion of the sale, the general counsel owned 630,398 shares of the company’s stock, valued at approximately $6,083,340.70. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Patrick Miles purchased 115,000 shares of the firm’s stock in a transaction dated Thursday, September 10th. The stock was acquired at an average price of $8.81 per share, with a total value of $1,013,150.00. Following the purchase, the chief executive officer directly owned 5,893,551 shares of the company’s stock, valued at approximately $51,922,184.31. The trade was a 1.99% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 13.48% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.